U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06943820) titled 'AK129 Combination Therapy for Advanced Solid Tumors' on April 06.
Brief Summary: This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma (CRC), and other advanced solid tumors.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Non-small Cell Lung Cancer Stage IIIB/IV
Head and Neck Squamous Cell Carcinoma (HNSCC)
Colorectal...